Levothyroxine Sodium Tablets
Subpotent Drug
Every FDA drug recall initiated in 2026, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
563 recalls, newest first.
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.
CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.
Failed Dissolution Specifications
Failed content uniformity specifications.
CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing
CGMP Deviations:Noted during FDA inspection
CGMP Deviations:Noted during FDA inspection
CGMP Deviations:Noted during FDA inspection
CGMP Deviations:Noted during FDA inspection
CGMP Deviations:Noted during FDA inspection
Presence of Particulate Matter: comprising polyethylene and other plastic materials, stainless steel and glass.
Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.
Lack of assurance of sterility. The recall is due to potential contamination
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials